ArticleBMC cancer2025
Clinical significance of NCOA4 in glioblastoma: diagnostic, prognostic, and therapeutic value.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioblastoma (GBM), classified as a WHO grade IV tumor, is associated with an extremely poor prognosis. Recent studies have identified NCOA4 as a crucial protein involved in ferritinophagy-induced ferroptosis. This research aims to investigate the clinical significance of NCOA4 in GBM.
methodsThe associations between NCOA4 and WHO grading, histology, clinicopathological characteristics, and prognosis were examined using the TCGA-GBMLGG, CGGA, and TCGA-GBM datasets, complemented by immunohistochemical experiments. Subsequently, the prognostic significance of NCOA4 was assessed through univariate and multivariate Cox regression analyses using the TCGA-GBM dataset. Moreover, the associations between NCOA4 and various infiltrating immune cells as well as their markers in GBM were investigated. Ultimately, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were utilized to elucidate the biological roles of NCOA4.
resultsNCOA4 expression significantly decreased with increasing WHO grade and malignancy of gliomas (p < 0.05), reaching the lowest levels in GBM (p < 0.05), indicating its potential diagnostic value. Low NCOA4 expression was significantly tied to a poor prognosis in GBM (p < 0.05) and functioned as an independent prognostic indicator (p < 0.05). It was also related to inadequate infiltration of B cells, macrophages, neutrophils, and dendritic cells (p < 0.05). Insufficient infiltration of B cells and macrophages could forecast a poor prognosis in GBM (p < 0.05). GO and KEGG analyses further confirmed NCOA4's involvement in ferroptosis and B cell signaling regulation pathways (p < 0.05).
conclusionsNCOA4's low expression in GBM correlates with tumor malignancy, adverse outcomes, and inadequate immune cell infiltration, suggesting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.